3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Gliosarcoma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
115
Bevacizumab
72
Radiotherapy
52
Radiation
23
Erlotinib Hydrochloride
13
Lomustine
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Vorinostat
10
Nivolumab
10
Surgical Procedures, Operative
9
Irinotecan
9
Sorafenib
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
7
Immunoglobulin G
7
Everolimus
7
Drug Therapy
7
Disulfides
7
Radiosurgery
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Carmustine
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Sirolimus
5
Cilengitide
5
veliparib
4
veledimex
4
temsirolimus
4
selinexor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioblastoma
×
Immunotherapy, Adoptive
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts